Get the Stockscreener App
0.6418
4.83%
-0.0326
Painreform Ltd stock is traded at $0.6418, with a volume of 58,961.
It is down -4.83% in the last 24 hours and down -33.46% over the past month.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
See More
Previous Close:
$0.6744
Open:
$0.66
24h Volume:
58,961
Relative Volume:
0.19
Market Cap:
$2.51M
Revenue:
-
Net Income/Loss:
$-9.34M
P/E Ratio:
-0.0899
EPS:
-7.14
Net Cash Flow:
$-6.69M
1W Performance:
-25.55%
1M Performance:
-33.46%
6M Performance:
-55.43%
1Y Performance:
-80.87%
1-Day Range:
$0.6403
$0.6744
1-Week Range:
$0.611
$0.8458
52-Week Range:
$0.611
$6.65
Painreform Ltd Stock (PRFX) Company Profile
Compare PRFX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRFX
Painreform Ltd
|
0.6418 | 2.64M | 0 | -9.34M | -6.69M | -7.14 |
|
ZTS
Zoetis Inc
|
125.82 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.11 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Painreform Ltd Stock (PRFX) Latest News
PainReform Ltd. (PRFX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PainReform Adjourns Annual Shareholder Meeting Due to Lack of Quorum - TipRanks
AI drones join $600B push to keep UAE and Middle East solar farms efficient - Stock Titan
Is PainReform Ltd stock attractive after correctionWeekly Stock Summary & Weekly Watchlist for Hot Stocks - moha.gov.vn
Why PainReform Ltd. stock remains on buy listsTrade Risk Summary & Daily Oversold Stock Bounce Ideas - Улправда
Can PainReform Ltd. stock surprise with earnings upside2025 Price Action Summary & Growth Focused Entry Reports - Улправда
Published on: 2025-12-19 20:32:49 - Улправда
Published on: 2025-12-19 20:05:02 - Улправда
Is PainReform Ltd. stock overvalued by current metricsWeekly Trend Recap & Daily Volume Surge Signals - Улправда
What hedge fund activity signals for PainReform Ltd. stockPrice Action & Long-Term Investment Growth Plans - DonanımHaber
How risky is PainReform Ltd. stock nowWall Street Watch & Long-Term Safe Investment Ideas - DonanımHaber
Is PainReform Ltd. stock attractive for income investorsWeekly Stock Summary & AI Powered Market Trend Analysis - Улправда
What drives PainReform Ltd stock priceTop Performing Stocks & Download Our Free Trading Blueprint - earlytimes.in
PainReform completed R&D assessment of LayerBio’s drug-delivery platform - MSN
Published on: 2025-12-13 11:33:01 - moha.gov.vn
Trend Recap: How PainReform Ltd stock performs after earningsQuarterly Investment Review & Proven Capital Preservation Methods - moha.gov.vn
PainReform’s LayerBio Platform Advances with Multi-Drug Capability - TipRanks
PainReform Ltd. Completes R&D Assessment of LayerBio's Sustained-Release Ocular Drug-Delivery Platform - Quiver Quantitative
PainReform (Nasdaq: PRFX) validates LayerBio drop-less ocular platform for multi-drug cataract care - Stock Titan
PainReform commences development plan for OcuRing-K Phase II trial - MSN
Is PainReform Ltd (PRFX) positioned for future growth? - Setenews
Will PainReform Ltd. stock pay special dividendsPortfolio Profit Report & Growth Oriented Trade Recommendations - Newser
Will PainReform Ltd. stock maintain dividend yieldMarket Volume Summary & Stock Portfolio Risk Management - Newser
PainReform Ltd. Commences Development for OcuRing??-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy - marketscreener.com
PainReform begins development plan for drop-less cataract surgery therapy By Investing.com - Investing.com
PainReform (PRFX) Advances OcuRing-K Development for Improved Ca - GuruFocus
PainReform Initiates Phase II Development for OcuRing™-K - TipRanks
Painreform commences development for Ocuring-K phase II trial - marketscreener.com
PainReform begins development plan for drop-less cataract surgery therapy - Investing.com
PainReform Commences Development for OcuRing™-K Phase II - GlobeNewswire
PainReform Ltd. (PRFX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
PainReform’s DeepSolar Advances with NVIDIA Connect and Pilot Projects - MSN
Can PainReform Ltd. stock deliver sustainable ROEJuly 2025 Price Swings & Daily Growth Stock Investment Tips - moha.gov.vn
PainReform schedules annual shareholder meeting for December 30 in Tel Aviv - Investing.com
PainReform Ltd. Announces December 2025 Shareholders Meeting with Key Proposals - TipRanks
Longview Tea Company Limited Stock Analysis Technical Signals for 2025High Beta Stocks & Small Investment Capital Tips - earlytimes.in
Is PainReform Ltd. stock recession proofQuarterly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Is PainReform Ltd. stock cheap at current valuationJuly 2025 Movers & Smart Swing Trading Techniques - newser.com
Will PainReform Ltd. bounce back from current supportEarnings Overview Summary & AI Driven Stock Movement Reports - newser.com
Price momentum metrics for PainReform Ltd. explainedMarket Performance Recap & Daily Technical Stock Forecast Reports - newser.com
Is PainReform Ltd. stock attractive for long term wealth buildingWeekly Gains Report & Expert Approved Trade Ideas - newser.com
Painreform Ltd Stock (PRFX) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.30%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):